Gaush Meditech Ltd
高视医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2407)

INSIDE INFORMATION
TRANSFER OF SHARES BY THE CHAIRMAN OF THE BOARD AND A CONTROLLING SHAREHOLDER

This announcement is published pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Share Transfer

Gaush Meditech Ltd (the "**Company**", together with its subsidiaries, the "**Group**") has been notified by Mr. Gao Tieta (高鐵塔), a controlling shareholder (as defined under the Listing Rules), an executive director and the chairman of the board of directors of the Company (the "**Board**"), that his wholly-owned company, GAUSH HOLDING Ltd (the "**Donor**" or "**GT HoldCo**"), entered into a deed of gift with Godax Ltd ("**Godax**") and Kleido Limited ("**Kleido**", together with Godax, the "**Donees**") on June 1, 2026, pursuant to which, the Donor will transfer 31,721,948 shares of a par value of US$0.0001 each of the Company (the "**Shares**"), representing approximately 21.45% of the Company's total issued share capital (the "**Relevant Shares**"), to the Donees (the "**Share Transfer**"), comprising (i) 7,320,450 Shares, representing approximately 4.95% of the Company's total issued share capital, to be transferred to Godax, and (ii) 24,401,498 Shares, representing approximately 16.50% of the Company's total issued share capital, to be transferred to Kleido. Godax is ultimately wholly owned by Mr. Gao Jinta (高金塔), who is the brother of Mr. Gao Tieta, and Kleido is ultimately wholly owned by Mr. Gao Ran (高然), who is the son of Mr. Gao Tieta. The purpose of the Share Transfer is mainly to re-allocate family assets among the family members and reinforce the family's collective commitment to the Group's future prosperity.

The Voting Proxy Arrangement

Notwithstanding the Share Transfer, considering Mr. Gao Tieta's consistent leadership in and significant contributions to the Group, as well as his proven industry expertise and management experience, each of the Donees entered into a deed of proxy (the "**Deed of Proxy**") with the Donor on June 1, 2026, pursuant to which, with effect immediately upon the completion of the Share Transfer, each of the Donees exclusively and irrevocably appoints the Donor as its proxy for exercising the voting rights in respect of the Relevant Shares in its sole discretion in the general meetings of the Company, until the date when it ceases to be a shareholder of the Company.

Effect on the Shareholding Structure of the Company

Upon completion of the Share Transfer, Mr. Gao Tieta will indirectly hold 31,541,580 Shares through GT HoldCo, representing approximately 21.33% of the Company's total issued share capital, and will continue to control the voting rights in respect of 63,263,528 Shares, representing approximately 42.78% of the Company's total issued share capital, which include the voting rights in respect of the Relevant Shares.

Set out below are the shareholding and voting rights held by the Donor and Donees immediately before and after the completion of the Share Transfer:

Ultimate beneficial owner	Name of shareholder of the Company	Number of Shares interested in immediately before the Share Transfer	Percentage of shareholding and voting rights	Number of Shares interested in immediately following the Share Transfer	Percentage of shareholding	Percentage of voting rights
Mr. Gao Tieta	GT HoldCo	63,263,528 Shares	42.78%	31,541,580 Shares	21.33%	42.78%
Mr. Gao Jinta	GMC FIVE Ltd ("**GMC V**")[1]	3,436,116 Shares	2.32%	3,436,116 Shares	2.32%	2.32%
	Godax	—	—	7,320,450 Shares	4.95%	—
	Sub-total	*3,436,116 Shares*	*2.32%*	*10,756,566 Shares*	*7.27%*	*2.32%*
Mr. Gao Ran	Kleido	—	—	24,401,498 Shares	16.50%	—
	Total	**66,699,644 Shares**	**45.10%**	**66,699,644 Shares**	**45.10%**	**45.10%**

Note:

1. GMC V is a management shareholding platform of the Company, which is owned as to 66.67% by Mr. Gao Jinta.

A ruling has been obtained from the Executive Director of the Corporate Finance Division of the Securities and Futures Commission that no obligation will arise on the part of the Donor and Donees to make a mandatory general offer for the Shares under Rule 26.1 of the Codes on Takeovers and Mergers and Share Buy-backs as a result of the Share Transfer.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Gaush Meditech Ltd
Mr. Gao Tieta
Chairman and Executive Director

Hong Kong, June 1, 2026

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive directors, Dr. David Guowei Wang as non-executive director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive directors.